quinidine has been researched along with cilostazol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bramer, SL; Suri, A | 1 |
| Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B | 1 |
| Aizawa, Y; Ashihara, T; Hasegawa, K; Horie, M; Itoh, H; Jo, H; Kimura, H; Yamamoto, T | 1 |
1 review(s) available for quinidine and cilostazol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for quinidine and cilostazol
| Article | Year |
|---|---|
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Area Under Curve; Cilostazol; Cross-Over Studies; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Quinidine; Tetrazoles; Vasodilator Agents | 1999 |
5 other study(ies) available for quinidine and cilostazol
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electrocardiography; Heart Conduction System; Hypothermia, Induced; Milrinone; Perfusion; Phosphodiesterase 3 Inhibitors; Quinidine; Signal Transduction; Tachycardia, Ventricular; Tetrazoles; Time Factors; Ventricular Fibrillation | 2014 |
Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Heart Conduction System; Humans; Male; Middle Aged; Phosphodiesterase 3 Inhibitors; Quinidine; Tetrazoles; Time Factors | 2014 |